Here’s what you need to know.
1. The company reported a smaller-than-expected quarterly profit from its dermatology and irritable bowel syndrome products, while cutting its full-year profit and revenue forecasts.
2. Since 2015’s peak of $257 per share, Valeant stock has tumbled more than 90 percent. It closed on Nov. 8, 2016 at $15.30 per share.
3. Valeant expects a total revenue of $9.55 billion to $9.65 billion for the year. The company projected $9.9 billion to $10.1 billion in total revenue.
4. Earnings were between $5.30 to $5.50 per share for the quarter. Projections expected quarterly earnings between $6.60 to $7 per share.
5. The company lost $1.22 billion or $3.49 per share in the third quarter. Last year the company posted a profit of $49.5 million or $0.14 a share.
6. The company’s revenue fell 11 percent to $2.48 billion which is under the $2.49 billion projection.
More articles on gastroenterology/endoscopy:
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
GI leader to know: Dr. Peyton Berookim of Gastroenterology Institute of Southern California
Following successful clinical trials, Bayer attempts to gain approval for liver cancer drug: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
